Literature DB >> 25670074

Cradle of evil: osteogenic niche for early bone metastasis.

Hanqiu Zheng1, Yibin Kang2.   

Abstract

Bone metastasis often emerges long after the initial dissemination of cancer cells. In this issue of Cancer Cell, Wang and colleagues demonstrate that disseminated breast cancer cells engage osteogenic niches in the bone through heterotypic adherins junctions. This interaction activates mTOR signaling in cancer cells and supports their expansion to micrometastases.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25670074     DOI: 10.1016/j.ccell.2015.01.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  5 in total

1.  AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway.

Authors:  Guang-Fu Hu; Cheng Wang; Guang-Xia Hu; Ge Wu; Chengjiao Zhang; Wei Zhu; Cong Chen; Yutong Gu; Hongwei Zhang; Zi'ang Yang
Journal:  Ann Transl Med       Date:  2020-03

2.  Breast cancer-secreted factors perturb murine bone growth in regions prone to metastasis.

Authors:  Aaron E Chiou; Chuang Liu; Inés Moreno-Jiménez; Tengteng Tang; Wolfgang Wagermaier; Mason N Dean; Claudia Fischbach; Peter Fratzl
Journal:  Sci Adv       Date:  2021-03-17       Impact factor: 14.136

3.  An Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis Landscapes.

Authors:  Ian H Guldner; Lin Yang; Kyle R Cowdrick; Qingfei Wang; Wendy V Alvarez Barrios; Victoria R Zellmer; Yizhe Zhang; Misha Host; Fang Liu; Danny Z Chen; Siyuan Zhang
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379

Review 4.  Emerging and Established Models of Bone Metastasis.

Authors:  Alexander H Jinnah; Benjamin C Zacks; Chukwuweike U Gwam; Bethany A Kerr
Journal:  Cancers (Basel)       Date:  2018-06-01       Impact factor: 6.639

Review 5.  Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.

Authors:  Buqing Sai; Juanjuan Xiang
Journal:  J Cell Mol Med       Date:  2018-09-26       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.